MedPath

Atazanavir

Generic Name
Atazanavir
Brand Names
Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)
Drug Type
Small Molecule
Chemical Formula
C38H52N6O7
CAS Number
198904-31-3
Unique Ingredient Identifier
QZU4H47A3S
Background

Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.

Indication

Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg.

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Clinical Trials
Related News

Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression

Phase 3
Completed
Conditions
Human Immunodeficiency Virus (HIV) Infections
Interventions
First Posted Date
2006-06-16
Last Posted Date
2010-07-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
61
Registration Number
NCT00337467
Locations
🇪🇸

Local Institution, Malaga, Spain

Pharmacokinetics of Atazanavir/Ritonavir in HIV-1 Infected Pregnant Women

Phase 1
Completed
Conditions
HIV Infection
Interventions
First Posted Date
2006-05-17
Last Posted Date
2011-11-16
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
69
Registration Number
NCT00326716
Locations
🇺🇸

Triple O Medical Services, P.A., West Palm Beach, Florida, United States

🇺🇸

Women's Hospital Of Texas, Houston, Texas, United States

🇿🇦

Local Institution, Westdene, Gauteng, South Africa

A Phase IV Study of BMS-232632 in HIV+ Patients With Metabolic Syndrome

Phase 4
Terminated
Conditions
HIV Infections
First Posted Date
2006-04-11
Last Posted Date
2016-09-19
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
70
Registration Number
NCT00312754
Locations
🇫🇷

Local Institution, Paris, France

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Phase 1
Completed
Conditions
HIV Infections
Interventions
Drug: Saquinavir/ritonavir
Drug: Atazanavir/ritonavir
Drug: Fos-amprenavir/ritonavir
Drug: Darunavir/ritonavir
Drug: Indinavir/ritonavir
First Posted Date
2006-03-28
Last Posted Date
2019-12-04
Lead Sponsor
Germans Trias i Pujol Hospital
Target Recruit Count
675
Registration Number
NCT00307502
Locations
🇪🇸

Hospital de Figueres, Figueras, Barcelona, Spain

🇪🇸

Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain

🇪🇸

Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain

and more 3 locations

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

Phase 3
Completed
Conditions
HIV Infection
Interventions
First Posted Date
2006-01-24
Last Posted Date
2015-03-30
Lead Sponsor
International Medical Center of Japan
Target Recruit Count
71
Registration Number
NCT00280969
Locations
🇯🇵

International Medical Center of Japan, Shinjuku, Tokyo, Japan

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Phase 1
Completed
Conditions
HIV Infections
Interventions
Procedure: Pharmacokinetic Study
First Posted Date
2005-12-01
Last Posted Date
2021-11-09
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
75
Registration Number
NCT00260078
Locations
🇺🇸

Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States

🇺🇸

Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States

🇺🇸

Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States

and more 20 locations

"The Once A Day Protease Inhibitor Regimens"

Phase 4
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2005-10-19
Last Posted Date
2014-01-15
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
76
Registration Number
NCT00242216
Locations
🇺🇸

Thomas Street Health Center, Houston, Texas, United States

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

Phase 4
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2005-09-23
Last Posted Date
2013-01-10
Lead Sponsor
Gilead Sciences
Target Recruit Count
100
Registration Number
NCT00224445
Locations
🇺🇸

Gilead Sciences, Inc., Foster City, California, United States

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

Phase 3
Completed
Conditions
HIV Infection
Hyperlipidemia
Interventions
Drug: current antiretroviral regimen
First Posted Date
2005-09-23
Last Posted Date
2012-08-02
Lead Sponsor
Northwestern University
Target Recruit Count
50
Registration Number
NCT00225017
Locations
🇮🇹

Universita degli studi di Modena e Reggio Emilia, Modena, Italy

🇦🇷

ACLIRES - Argentina S.R.L., Buenos Aires, Argentina

🇺🇸

University of California, San Diego, California, United States

and more 4 locations

Induction-Maintenance With Atazanavir in HIV Naïve Patients (The INDUMA Study)

Phase 4
Completed
Conditions
HIV Infections
Interventions
First Posted Date
2005-09-21
Last Posted Date
2010-01-12
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
252
Registration Number
NCT00207142
Locations
🇬🇧

Local Institution, London, Greater London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy